Nephrology

Back to articles

Mycophenolate mofetil: No benefit, serious adverse effects in patients with MGN

KEY POINT

Mycophenolate mofetil (MMF) (CellCept— Roche) does not appear to improve proteinuria or increase remissions in adults with membranous glomerulonephritis (MGN). In addition, serious adverse effects limit the potential for MMF in this patient population.

SOURCES

Dussol B et al. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kid Dis. 2008;52:699–705.

 CellCept package insert. Roche Laboratories, Inc. Nutley, NJ. May 2008.